UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Health Management Associates
In a report published Friday, Deutsche Bank reiterated its Buy rating on Health Management Associates (NYSE: HMA), and slightly raised its price target from $11.00 to $12.00.
Deutsche Bank noted, “We are presenting updated estimates to include the impending Bayfront Medical Center acquisition in St. Petersburg, FL (expected closing end of Q1) and to conform our pro forma EPS estimates with First Call consensus and HMA's guidance format, which excludes meaningful use incentive payments and unusual swap expense. Despite the noise of HMA's government investigation and fall-out from the recent 60 Minutes story, we continue to like the risk/reward in HMA shares. We believe HMA's exposure to these issues will be small, while its growth potential is solid, especially in the context of margin upside from PPACA in 2014. Reiterate Buy.”
Health Management Associates closed on Thursday at $9.55.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tags: Deutsche Bank